A5007159753- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Liver Disease Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Research Studies
- Cancer Mechanisms and Therapy
- Cancer, Lipids, and Metabolism
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Liver physiology and pathology
- Urinary and Genital Oncology Studies
- Hepatitis B Virus Studies
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Economic and Financial Impacts of Cancer
- Hepatitis C virus research
- Cancer Research and Treatments
- Multiple Myeloma Research and Treatments
California Pacific Medical Center
2016-2025
Pacific Eye Associates
2006-2023
Hematology Oncology Associates
2006-2023
Sutter Health
2014-2021
Merck & Co., Inc., Rahway, NJ, USA (United States)
2019
First Hospital of China Medical University
2013
Intensive Care Foundation
2013
Keio University
2013
Ghent University Hospital
2012
Huntsman (United States)
2012
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity metastatic colorectal cancer, particularly in combination with chemotherapy.
PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study plus pembrolizumab (an anti–PD-1 antibody) unresectable HCC (uHCC). PATIENTS AND METHODS In this open-label multicenter study, patients uHCC received (bodyweight ≥ 60 kg, 12 mg; < 8 mg) orally daily and...
The optimal trastuzumab-based chemotherapy regimen for HER2-overexpressing, metastatic breast cancer is not known. trastuzumab and vinorelbine or taxane (TRAVIOTA) study was a prospective, multicenter, randomized trial that designed to compare these regimens.Eligible patients had received no prior advanced disease. Patients were 1:1 receive either with weekly therapy (paclitaxel docetaxel at the investigator's choice). Originally planned 250 patients, closed because of poor accrual 81...
We tested the hypothesis that certain patients with hormone refractory prostate cancer retain hormonal sensitivity even after progression following antiandrogen withdrawal. The efficacy of ketoconazole and hydrocortisone in this patient population was evaluated.A total 50 consecutive advanced received at Prostate specific antigen (PSA) response defined as greater than a 50% decrease PSA from baseline maintained for least 8 weeks.Overall, 48 evaluable 30 (62.5%, 95% confidence interval 47.3...
4076 Background: LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT that showed noninferiority with respect to overall survival (OS) compared sorafenib in the first-line treatment pts uHCC phase (Ph) 3 trial (REFLECT). PEM an anti-PD-1 monoclonal antibody has shown promising activity HCC. An ongoing Ph 1b study + several solid tumor types. We report preliminary results from Ph1b uHCC. Methods: In this open-label, multicenter study, uHCC, BCLC stage B (not eligible...
Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while stimulating anti-tumor immunity by expressing GM-CSF. An earlier randomized Phase IIa trial predominantly sorafenib-naïve hepatocellular carcinoma (HCC) demonstrated an overall survival (OS) benefit. This randomized, open-label IIb investigated whether Pexa-Vec plus Best Supportive Care (BSC) improved OS over BSC alone HCC patients who...
Abstract Purpose: In REFLECT, lenvatinib demonstrated an effect on overall survival (OS) by confirmation of noninferiority to sorafenib in unresectable hepatocellular carcinoma. This analysis assessed correlations between serum or tissue biomarkers and efficacy outcomes from REFLECT. Experimental Design: Serum (VEGF, ANG2, FGF19, FGF21, FGF23) were measured ELISA. Gene expression tumor tissues was the nCounter PanCancer Pathways Panel. Pharmacodynamic changes biomarker levels baseline,...
715 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results from cohort PC BRCA1/2 mut treated N+I are reported. Methods: Eligible had measurable disease, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment (tx) options or prior immune checkpoint inhibitor tx. PD-L1 expression testing was not required. Genomic performed CLIA-certified,...
Brief Reports15 June 1992The Sweet Syndrome during Therapy with Granulocyte Colony-stimulating FactorJohn W. Park, MD, Bhoomi Mehrotra, Bryan O. Barnett, Ari D. Baron, Alan P. Venook, MDJohn MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-12-996 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptGranulocyte colony-stimulating factor (G-CSF; filgrastim), a hematopoietic growth...
Abstract Purpose: Thalidomide and its more potent immunomodulatory derivative lenalidomide enhance rituximab-mediated antibody-dependent cell-mediated cytotoxicity. We therefore evaluated rituximab in symptomatic Waldenstrom's macroglobulinemia (WM) patients naive to either agent. Experimental Design: Intended therapy consisted of 48 weeks (25 mg/d for 3 then 1 week off) along with (375 mg/m2/wk) dosed on 2 5 13 16. Sixteen were enrolled, 12 whom previously untreated. Results: Unexpectedly,...
4001 Background: SOR is the only approved agent in uHCC and new options are needed. LEN, an inhibitor of vascular endothelial growth factor receptors 1‒3, fibroblast 1‒4, platelet derived receptor α, RET, KIT, showed activity a phase II trial. We report III trial LEN vs as first-line therapy for uHCC. Methods: In this randomized, open-label, noninferiority (NI) study, pts had uHCC, ≥ 1 measurable target lesion, Barcelona Clinic Liver Cancer stage B or C, Child-Pugh class A, ECOG PS ≤ 1, no...
REACH is the first phase 3 trial to provide information on hepatocellular cancer (HCC) in second-line (postsorafenib) setting categorized by Child-Pugh score, a scoring system used measure severity of chronic liver disease. This exploratory analysis demonstrates relationship between potential ramucirumab survival benefit, disease, and baseline α-fetoprotein (αFP).To assess treatment effects tolerability score patients with HCC enrolled trial.Randomized, double-blind, best supportive care vs...
Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is highly expressed in cancers. DSTP3086S a humanized immunoglobulin G1 anti-STEAP1 monoclonal antibody linked to potent antimitotic agent monomethyl auristatin E. This study evaluated safety and activity patients with metastatic castration-resistant cancer.Patients were enrolled 3 + dose escalation evaluate (0.3 2.8 mg/kg intravenously) given once every weeks followed by cohort expansion at recommended phase II or weekly (0.8...
ObjectiveIn the phase 3 CELESTIAL trial, cabozantinib improved overall survival (OS) and progression-free (PFS) compared with placebo in patients previously treated advanced hepatocellular carcinoma (HCC). This subgroup analysis evaluated who had received sorafenib as only prior systemic therapy.MethodsCELESTIAL randomised (2:1) HCC Child–Pugh class A liver function to treatment (60 mg daily) or placebo. Eligibility required sorafenib, could have ≤2 regimens. The primary endpoint was OS....
4519 Background: LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT, approved for first line (1L) treatment uHCC. PEMBRO, an anti-PD-1 monoclonal antibody, was granted accelerated approval the patients (pts) with HCC after sorafenib therapy. We assessed safety efficacy + PEMBRO in Methods: In this phase 1b trial (NCT03006926), pts received 12 mg/day (bodyweight [BW] ≥60 kg) or 8 (BW <60 orally 200 mg IV on Day 1 21-day cycle. Primary endpoints were tolerability...
Baseline liver function among patients starting treatment for unresectable hepatocellular carcinoma (uHCC) impacts survival and could impact efficacy outcomes safety profiles of treatments. This post hoc analysis the phase 3 REFLECT study examined lenvatinib sorafenib in with uHCC, assessed by Child-Pugh score (CPS) albumin-bilirubin (ALBI) grade.Efficacy were patient cohorts from according to entry baseline ALBI grade CPS.Lenvatinib generally provided benefits all groups. Median overall...
Increased survival with immune checkpoint inhibitors has been reported for patients obesity vs a normal body mass index (BMI). However, the association of safety warrants study.To investigate associations between BMI and immune-related adverse events (irAEs) among advanced cancers treated nivolumab monotherapy plus ipilimumab combination therapy.This study was retrospective pooled analysis 3772 from 14 multicenter CheckMate clinical trials across 8 tumor types. Patients received nivolumab, 3...
BACKGROUND Although antiandrogen withdrawal has moderate efficacy in patients with hormone refractory prostate carcinoma (HRPC), the effect of simultaneous suppression adrenal androgens ketoconazole at time is not known. METHODS Twenty consecutive HRPC who had developed progressive disease despite combined androgen blockade were treated and as a means inhibiting steroid production. Prostate specific antigen (PSA) response was defined > 50% fall PSA from baseline that maintained for least 8...